Facebook
Twitter
Telegram
Report an ErrorVir Biotechnology Balance Sheet 2011-2024 | VIR
Annual Balance Sheet Vir Biotechnology
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-117 M | -721 M | -210 M | -366 M | -109 M | -47.6 M | -188 M | - | - | - | - | - | - |
Long Term Debt |
112 M | 124 M | 134 M | 66.6 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
12.9 M | 4.14 M | 3.93 M | 3.62 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 28.9 M | 331 M | 308 M | - | - | - | - | - | - |
Total Current Liabilities |
175 M | 511 M | 341 M | 99.1 M | 59.2 M | - | - | - | - | - | - | - | - |
Total Liabilities |
329 M | 724 M | 522 M | 202 M | 88.1 M | 371 M | 320 M | - | - | - | - | - | - |
Deferred Revenue |
64.9 M | 15.5 M | 98.2 M | 6.45 M | 6.18 M | 8.76 M | - | - | - | - | - | - | - |
Retained Earnings |
-238 M | 377 M | -139 M | - | -369 M | -194 M | -78 M | - | - | - | - | - | - |
Total Assets |
1.92 B | 2.8 B | 1.95 B | 919 M | 512 M | 192 M | 252 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
242 M | 849 M | 348 M | 437 M | 109 M | 47.6 M | 189 M | - | - | - | - | - | - |
Book Value |
1.59 B | 2.08 B | 1.43 B | 717 M | 424 M | -179 M | -68.9 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.59 B | 2.08 B | 1.43 B | 717 M | 424 M | -179 M | -68.9 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Vir Biotechnology
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
109 M | 112 M | 114 M | 118 M | 121 M | 124 M | 127 M | 130 M | 133 M | 134 M | 68.6 M | 68.9 M | 66.6 M | 700 K | 700 K | 800 K | 800 K | 900 K | 900 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
247 M | 329 M | 370 M | 434 M | 695 M | 724 M | 546 M | 667 M | 886 M | 522 M | 334 M | 320 M | 485 M | 202 M | 202 M | 202 M | 202 M | 88.1 M | 88.1 M | 88.1 M | 88.1 M | 61.6 M | 61.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
14.7 M | 64.9 M | 15.3 M | 15.7 M | 17.2 M | 15.5 M | 22.9 M | 113 M | 114 M | 98.2 M | 96.2 M | 44.7 M | 263 M | 6.45 M | 6.45 M | 6.45 M | 6.45 M | 6.18 M | 6.18 M | 6.18 M | 6.18 M | 8.76 M | 8.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-303 M | -238 M | -122 M | 41.6 M | 236 M | 377 M | 479 M | 304 M | 380 M | -139 M | -664 M | 774 M | -836 M | -667 M | -667 M | 667 M | -667 M | -369 M | -369 M | -369 M | -369 M | -194 M | -194 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.79 B | 1.92 B | 2.04 B | 2.24 B | 2.67 B | 2.8 B | 2.7 B | 2.62 B | 2.89 B | 1.95 B | 1.21 B | 1.06 B | 1.14 B | 919 M | 919 M | 919 M | 919 M | 512 M | 512 M | 512 M | 512 M | 192 M | 192 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
161 M | 242 M | 452 M | 667 M | 825 M | 849 M | 964 M | 1.51 B | 812 M | 348 M | 715 M | 742 M | 521 M | 451 M | 437 M | 437 M | 437 M | 109 M | 109 M | 109 M | 109 M | 47.6 M | 47.6 M | - | - | 188 M | - | - | - | 14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.55 B | 1.59 B | 1.68 B | 1.81 B | 1.97 B | 2.08 B | 2.15 B | 1.95 B | 2 B | 1.43 B | 876 M | 737 M | 651 M | 717 M | 717 M | 717 M | 717 M | 424 M | 424 M | 424 M | 424 M | 130 M | 130 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.55 B | 1.59 B | 1.68 B | 1.81 B | 1.97 B | 2.08 B | 2.15 B | 1.95 B | 2 B | 1.43 B | 876 M | 737 M | 651 M | 717 M | 717 M | 717 M | 717 M | 424 M | 424 M | 424 M | 424 M | -179 M | -179 M | -122 M | - | -68.9 M | - | - | - | -7.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency